Noboru Yamamoto

机构：National Cancer Centre Japan, National Cancer Center, National Cancer Center Hospital East, Tokyo National Hospital, National Cancer Research Institute · ORCID：0000-0002-0787-2851

发表论文 1268 篇 · 总被引 18657 次 · h-index 67

代表论文

• Table S4 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors (2026)
• Figure 1 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors (2026)
• Table S3 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors (2026)
• Table S5 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors (2026)
• Supplementary Table S2 from The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with <i>KRAS</i> Mutation-Positive Solid Tumors (2026)
• Table S1 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors (2026)